P3 HEALTH PARTNERS INC Stock Price, News & Analysis

P3 Health Partners Inc. (NASDAQ: PIII) reported its Q4 and full-year 2022 financial results, with a notable 40% increase in capitated revenue to $254.0 million. However, the company faced a substantial net loss of $532.3 million, primarily due to a goodwill impairment charge of $463.5 million. For the full year, P3's at-risk Medicare Advantage membership grew by 50% to 100,400, with total revenues reaching $1.0 billion, a 66% increase from the previous year. Looking forward, P3 anticipates achieving Adjusted EBITDA positivity by early 2024 and has provided fiscal 2023 guidance with total revenues projected between $1.2 billion and $1.25 billion.

P3 Health Partners Inc. (NASDAQ: PIII) announced a definitive agreement for a private placement of securities, expected to yield approximately $90 million in gross proceeds. The lead investors are affiliates of Chicago Pacific Founders and Leavitt Partners. The company will issue 79.9 million units at about $1.12 per unit, which includes one share of common stock and 0.75 of a warrant for each unit. The funds will be used for general corporate purposes, and the transaction's closing is anticipated for April 6, 2023.

P3 Health Partners Inc. (NASDAQ: PIII) announced it will release its fourth-quarter 2022 and full-year 2022 results on March 31, 2023, before the market opens. Management will host a conference call and webcast at 8:30 AM ET on the same day to discuss corporate and financial updates. P3 is a physician-led population health management company with over 2,800 affiliated primary care providers across five states. The call details will be provided on the company’s investor page, and an archived recording will be available for 90 days post-event.

P3 Health Partners Inc. (NASDAQ: PIII) plans to release its financial results for the fourth quarter and full year ending December 31, 2022, on March 30, 2023. The company will also file its Annual Report on Form 10-K on the same day. An investor call and webcast are scheduled for 4:30 PM ET to discuss the financial performance and provide a corporate update. P3 Health Partners focuses on improving healthcare through a network of over 2,800 affiliated primary care providers across five states. Further details will be available on their investor relations page.

P3 Health Partners Inc. (NASDAQ: PIII) announced its intention to file the Annual Report on Form 10-K by March 30, 2023. The delay is attributed to an administrative issue related to the delayed audit for 2021. P3 reaffirmed its 2022 revenue guidance of $1.025 billion to $1.075 billion, representing a 61% to 69% increase year-over-year. They expect at-risk Medicare Advantage membership to exceed 100,000, a 35% rise from 2021. The 2023 guidance includes revenue expectations of $1.20 billion to $1.25 billion and an Adjusted EBITDA loss of $40 million to $60 million. P3 anticipates achieving Adjusted EBITDA profitability by 2024.

P3 Health Partners Inc. (NASDAQ: PIII), a physician-led population health management company, announced that Dr. Amir Bacchus, Co-founder and Chief Medical Officer, will participate in a fireside chat at the Jefferies Value-Based Care Summit in Miami Beach, FL on March 13, 2023, at 2:45 PM ET. Additionally, Dr. Bacchus will present at the Barclays Global Healthcare Conference on March 14, 2023, at 4:35 PM ET, with a live audio webcast available. P3 Health Partners is committed to improving healthcare outcomes through value-based care coordination, managing over 2,800 affiliated primary care providers across five states.

P3 Health Partners Inc. (NASDAQ: PIII) has announced that CEO Dr. Sherif Abdou will present at the TD Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, at 1:30 PM Eastern Time. The presentation will include insights into the company's patient-centered healthcare model and strategies for improving patient outcomes. A live audio webcast of the presentation will be available on P3’s website, along with a replay for 30 days post-event. P3 Health Partners focuses on population health management, collaborating with over 2,800 primary care providers across five states.

P3 Health Partners Inc. (NASDAQ: PIII) is participating in J.P. Morgan’s 41st Annual Healthcare Conference in San Francisco from January 9-12, 2023. The Company reaffirms its 2022 revenue guidance of $1.025 billion to $1.075 billion, reflecting a 61% to 69% increase from 2021. For 2023, P3 expects Medicare Advantage membership to grow to 115,000-120,000 and revenue between $1.20 billion and $1.25 billion. Adjusted EBITDA loss is forecasted at $40 million to $60 million, with expectations for positive Adjusted EBITDA in 2024.

P3 Health Partners Inc. (NASDAQ: PIII) will participate in J.P. Morgan’s 41st Annual Healthcare Conference in San Francisco from January 9-12, 2023. Dr. Sherif Abdou, the co-founder and CEO, is scheduled to present on January 11 at 5:15 pm Pacific Time. A live audio webcast of the presentation will be accessible here, with a replay available for 30 days on P3's investor relations webpage. P3 Health Partners focuses on population health management, serving over 100,000 patients with a network of 2,500 providers in five states.